Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best healthcare stocks with a high upside potential. H.C. Wainwright raised its price target on OCUL to $19 from $15, maintaining a Buy rating after FDA granted a Special Protocol Assessment for AXPAXLI in NPDR treatment.

OCUL reported new Phase 3 trials, HELIOS-2 and HELIOS-3, for NPDR. HELIOS-2 compares AXPAXLI to ranibizumab, while HELIOS-3 assesses different AXPAXLI dosing regimens. The firm expects potential AXPAXLI sales to increase OCUL’s market value to $3.97 billion.

Ocular Therapeutix Inc. (NASDAQ:OCUL) is a biopharmaceutical company focusing on eye-related therapies. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. While OCUL shows promise, some AI stocks may offer greater upside potential and less risk in the current market environment.

Read more at Yahoo Finance: H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating